Calton & Associates, Inc. Sellas Life Sciences Group, Inc. Transaction History
Calton & Associates, Inc.
- $412 Million
- Q1 2025
A detailed history of Calton & Associates, Inc. transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Calton & Associates, Inc. holds 11,000 shares of SLS stock, worth $18,040. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,000
Previous 4,636
137.27%
Holding current value
$18,040
Previous $5,000
120.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SLS
# of Institutions
52Shares Held
14.5MCall Options Held
538KPut Options Held
26.3K-
Anson Funds Management LP Dallas, TX7.58MShares$12.4 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.84MShares$4.66 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA820KShares$1.35 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA689KShares$1.13 Million0.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$705,8030.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $33.7M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...